Newsroom

What:

The federal government has expanded the Home Test to Treat program, an entirely virtual community health program that offers free COVID-19 health services: at-home rapid tests, telehealth

NIH will advance the development of home-based and point-of-care health technologies with awards to six technology research and development centers around the country. The centers comprise the Point of Care Technology Research Network (POCTRN) and will parlay the momentum of the original network established in 2007 by the NIBIB.

The Rapid Acceleration of Diagnostics Technology (RADx® Tech) Fetal Monitoring Challenge calls on scientists, engineers, and clinicians around the country to submit their innovative approaches and compete for prizes and additional resources to support technology development and clinical impact.

The National Institutes of Health and the higher education non-profit VentureWell have selected 10 winners and five honorable mentions of the Design by Biomedical Undergraduate Teams (DEBUT) Challenge

NIBIB has established the Center for Biomedical Engineering Technology Acceleration—BETA Center, a new intramural research program to solve a range of medicine’s most pressing problems. The BETA Center will serve the wider NIH intramural research program as a biotechnology resource and catalyst for NIH research discoveries.

NIH has launched the Home Test to Treat program, an entirely virtual community health intervention that will provide free COVID-19 health services—at-home rapid tests, telehealth sessions and at-home treatments—in selected communities.

Reporting a positive or negative test result just became easier through a new website from the National Institutes of Health. MakeMyTestCount.org, developed through NIH’s Rapid Acceleration of Diagnostics (RADx®) Tech program, allows users to anonymously report the results of any brand of at-home COVID-19 test.

A research team funded by the National Institutes of Health has shown that commercially available rapid antigen tests can detect past and present variants of concern and has identified potential mutations that may impact test performance in the future.

NIH has issued two new funding opportunities for diagnostic test manufacturers to develop the next generation of COVID-19 diagnostics.